What’s Next? Five Things To Look Out For In September
More Revlimid Rivals Ready In The US; Stephan Sturm Departs Fresenius
As the fourth quarter of the year nears, plenty is on the horizon for industry, with senior management shifts and a slate of high-value launches in the US and Europe.
You may also be interested in...
Fresenius Kabi CEO Michael Sen is set to replace Fresenius group chief executive Stephan Sturm from the start of October. He will remain head of Kabi until a successor is appointed.
The European Commission has approved Vegzelma, a bevacizumab biosimilar developed by South Korean biopharma giant Celltrion. Vegzelma joins nine other bevacizumab biosimilar marketing authorization applications approved in the EU, promising to intensify price competition for the critical late-stage cancer treatment.
Pinning its hopes on its proposed bevacizumab product for ophthalmic indications, Outlook Therapeutics has been told to give more information to the US FDA ahead of an approval. However, one analyst remained upbeat for the company’s prospects.